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Abstract
Background: A previous study has shown that variations in threshold and intensity (lipid goal attainment)
of statins for primary prevention contribute to regional differences in overall consumption of statins in
Norway. Our objective was to explore how differences in prevalences of use, dosing characteristics,
choice of statin and continuity of therapy in individual patients adds new information to previous results.
Methods: Data were retrieved from The Norwegian Prescription Database. We included individuals from
counties with high, average, and low statin consumption, who had at least one statin prescription dispensed
during 2004 (N = 40 143).
1-year prevalence, prescribed daily dose (PDD), statin of choice, and continuity of therapy assessed by
mean number of tablets per day.
Results: The high-consumption county had higher prevalence of statin use in all age groups.
Atorvastatin and simvastatin were dispensed in 79–87% of all statin users, and the proportion was
significantly higher in the high-consumption county.
The estimated PDDs were higher than the DDDs, up to twice the DDD for atorvastatin. The high-
consumption county had the highest PDD for simvastatin (25.9 mg) and atorvastatin (21.9 mg), and more
users received tablets in the upper range of available strengths. Continuity of therapy was similar in the
three counties.
Conclusion: Although differences in age-distribution seems to be an important source of variation in
statin consumption, it cannot account for the total variation between counties in Norway. Variations in
prevalences of use, and treatment intensity in terms of PDD and choice of statin also affect the total
consumption. The results in this study seems to correspond to previous findings of more frequent statin
use in primary prevention, and more statin users achieving lipid goal in the highest consuming county.
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During the last decade clinical data on the benefits of stat-
ins in the prevention of cardiovascular disease have accu-
mulated [1]. Statin consumption, measured as defined
daily doses (DDDs) per 1000 inhabitants per day, has
increased remarkably in Norway, and is high compared
with other European countries [2,3]. However, there are
large and persistent regional differences in statin con-
sumption in Norway [3]. In 2004, the top-consumption
county, Hedmark, had a sales volume that was twice the
level in the low-consumption county, Troms, and 40%
higher than the neighbouring county, Oppland (Figure 1)
[3]. Ideally, geographical variations of statin consumption
should reflect variations in the size of population eligible
for such therapy, as defined by the guidelines. However,
according to our previous findings in a population-based
study from Hedmark and Oppland, the presence of cardi-
ovascular morbidity and risk factors were similar in the
populations in the two counties [4]. Still our previous
study indicated that more people received statins for pri-
mary prevention in the high-consumption county Hed-
mark. In addition, the statin users in the primary
prevention subgroup seemed to be treated more inten-
sively, as reflected in the higher attainment of total choles-
terol (TC) targets among statin users in Hedmark [4]. The
success in achieving the TC target might, however, be
influenced by the use of higher dosages of statins and/or
continuity of use. Based on prescription data, the main
objective of the present study was to explore the following
aspects of statin use in three counties with high (Hed-
mark), average (Oppland) and low (Troms) total statin
consumption: prevalences of use, dosing characteristics,
choice of statin and continuity of therapy.
Methods
The Norwegian Prescription Database
Data were retrieved from the Norwegian Prescription
Database (NorPD), which includes prescription data from
the total population (4.6 million) in Norway since 2004
[5,6]. The NorPD contains information from all prescrip-
tion drugs, reimbursed or not, dispensed at pharmacies to
individual patients living outside institutions. The iden-
tity of patients has been encrypted, but each record con-
tains a unique person identifier, which makes it possible
to identify all prescriptions for individuals.
We included persons from three counties with high (Hed-
mark), average (Oppland) and low (Troms) statin con-
sumption; each individual had at least one prescription of
a statin (ATC group C10AA) dispensed during 2004. In
total, 40 143 statin users were included in our analysis: 17
954, 13 348 and 8841 from the high-, average- and low-
consumption counties, respectively. The data collected
were: patient's sex, age and place of residence; date of dis-
pensing; and drug information (brand name, package
size, number of packages, ATC code, DDD). Statin use in
institutions (hospitals and nursing homes) accounted for
less than 2% of the total statin consumption in Norway in
2004, and is not included in this analysis.
Definitions
Period (1-year) prevalence of use was estimated by identi-
fication of individuals who had at least one statin pre-
scription dispensed during 2004.
Distribution of all statin users according to prescribed sta-
tin substance was defined by the first prescription dis-
pensed in 2004.
Information about the prescribed daily dose (PDD) is not
yet available from the NorPD. However, statins are avail-
able in many tablet strengths [7], and validation of statins
in other prescription databases have shown that the dis-
pensed tablet strength concords highly with the PDD [8].
Based on the assumption that all users take one tablet
daily, a surrogate for the PDD was calculated for all statins
from the total volume dispensed in milligrams divided by
the total number of dispensed tablets; this gave a mean
PDD per county for all statins. In addition, the distribu-
tion of all statin users, according to tablet strength on the
first prescription dispensed in 2004, was studied.
Continuity of statin use between two prescription retriev-
als was explored under the assumption of the use of one
tablet per day as the unit. Hence, when the number of
days between two prescriptions did not exceed the
number of tablets dispensed by the first prescription, con-
tinuity in this period can be assumed. For every prescrip-
tion followed by another prescription in the same patient,
Sales of statins (ATC group C10AA) in Defined Daily Doses (DDDs) per 1000 inhabitants per day in thre  Norwegian counties and Norway as  whol , 1996–2004Figur 1
Sales of statins (ATC group C10AA) in Defined Daily Doses 
(DDDs) per 1000 inhabitants per day in three Norwegian 
counties and Norway as a whole, 1996–2004. Wholesale sta-
tistics, Norwegian Institute of Public Health [3].
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was divided by the number of days between the two pre-
scriptions, which gave a mean daily use of tablets (tablets/
day).
Statistics
All analyses were done using SPSS 12.0 for Windows. Age
and sex standardisation of total period prevalence of sta-
tin use was done by the direct method (5-year intervals)
using the Norwegian population as the standard [9]. Pro-
portions with 95% confidence intervals were used to
describe statin users according to choice of statin and
retrieved tablet strength in the counties. The distribution
of the number of tablets/day between two prescription
retrievals was skewed, and thus described by medians and
interquartile ranges (IQR).
Results
Prevalence of statin use
Figure 2 presents 1-year prevalence according to age and
sex among individuals who had at least one statin dis-
pensed during 2004. The crude prevalence (age adjusted)
for men in the different counties were: 10.3% (8.9%),
7.8% (6.9%) and 6.4% (6.4%) in the high-, average- and
low-consumption counties, respectively. The correspond-
ing figures for women were: 8.8% (7.5%), 6.9% (6.0%)
and 5.3% (5.4%).
The high-consumption county had higher prevalence of
statin use in all age groups, even though the differences
were minimised in the age adjusted prevalences. Only
minor differences were observed between the two other
counties. More men than women were on statins, and sta-
tin use increased by age in all three counties, peaking
among 70- to 79-year-old individuals in both sexes. The
prevalence of use in people aged 80 years and older was
only 50% compared with the 70–79 year olds, in all coun-
ties.
Choice of statin
Atorvastatin accounted for 42–47%, simvastatin for 37–
40% and pravastatin for the remaining 9–17% of all statin
users in the three counties (Figure 3). More users in the
high-consumption county Hedmark were prescribed ator-
vastatin and simvastatin, whereas pravastatin constituted
a larger proportion of all statin users in the two other
counties.
Prescribed daily dose
More users in the high-consumption county were pre-
scribed simvastatin and atorvastatin in the upper range of
the clinically available strengths, including 'high-dose
therapy' (atorvastatin and simvastatin of 80 mg) (Figure
4). The high-consumption county had the highest PDD
for simvastatin (25.9 mg) and atorvastatin (21.9 mg)
One-year prevalence (%) of use of statins in three Norwe-gian counties by age and gender. Norwegia  Prescription D tabase 2004Figur  2
One-year prevalence (%) of use of statins in three 
Norwegian counties by age and gender. Norwegian 
Prescription Database 2004. High-c county: abbreviation 
for high-consumption county.
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Proportion of all users according to different statins pre-scribed n three Norwegian counties 1. Norwegian Prescrip-tion Database 2004Figure 3
Proportion of all users according to different statins 
prescribed in three Norwegian counties 1. Norwegian 
Prescription Database 2004. High-c county: abbreviation 
for high-consumption county. 1 Statin substance according to 
the first prescription dispensed in 2004.
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higher than the DDDs – up to twice the DDD for atorvas-
tatin.
Continuity of treatment (tablets/day)
The number of prescriptions followed by another pre-
scription in the same individual were 43 045 in 17 954
individuals in Hedmark, 29 971 in 13 348 individuals in
Oppland and 19 770 in 8841 individuals in Troms.
The distribution of the mean number of tablets per day for
all prescriptions followed by another prescription was
similar in the counties. Medians (IQR) in these distribu-
tions were 1.05 (0.94–1.39), 1.04 (0.94–1.34) and 1.05
(0.93–1.42) in Hedmark, Oppland and Troms, demon-
strating that the users retrieved statins corresponding to
the use of one tablet per day.
Discussion
Although differences in age-distribution seems to be an
important variable in the explanation of differences statin
consumption, it does not fully outweigh the inter-county
variation of statin consumption in Norway. Variations in
prevalences of use, and treatment intensity in terms of
PDD and choice of statin also affect the total consump-
tion.
Not surprisingly, the estimated PDDs for all statins were
higher than the DDDs – up to twice the DDD for atorvas-
tatin. The official DDDs for all statins have remained
unchanged since 1994 and have not been adjusted to the
new clinical documentation published over the last dec-
ade [10]. As indicated from all statin prescriptions dis-
pensed for the first time in 2004; extensive use of
atorvastatin, combined with a systematically higher PDD
for all relevant statins in the high-consumption county
Hedmark, influences total level of, and thereby variation
in, statin consumption.
A limitation with this study is the lack of information on
statin use in relation to other relevant patient characteris-
tics such as cardiovascular morbidity and risk factors,
including clinical measurements. However, the tendency
of an overall more aggressive cholesterol treatment in the
high-consumption county, Hedmark, is in line with previ-
ous findings from our population-based study in Hed-
mark and the average-consumption county, Oppland: a
higher proportion of the statin users in Hedmark achieved
the nationally recommended TC target [4]. Although we
do not know to what extent LLDs dispensed actually are
ingested, patterns of the number of tablets dispensed per
day were similar between the counties in our present
study. Thus, the success in achieving TC target in Hedmark
Proportion of statin users according to tablet strength of simvastati and atorvastatin in three Norwegian counties 1. N rwegia Prescr ption D tabase 2004Figur  4
Proportion of statin users according to tablet 
strength of simvastatin and atorvastatin in three 
Norwegian counties 1. Norwegian Prescription Data-
base 2004. High-c county: abbreviation for high-consump-
tion county. 1Tablet strength according to the first 
prescription dispensed in 2004.
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Table 1: Mean prescribed daily dose (PDD) in milligrams of the different statins in three Norwegian counties1. Norwegian Prescription 
Database 2004
Statin substance (C10AA) DDD2 High-c county (Hedmark) mg Average-c county (Oppland) mg Low-c county (Troms) mg
Simvastatin (C10AA01) 15 25.9 24.0 22.5
Lovastatin (C10AA02) 30 31.8 30.3 28.2
Pravastatin (C10AA03) 20 32.1 32.1 32.3
Fluvastatin (C10AA04) 40 60.9 58.7 57.3
Atorvastatin (C10AA05) 10 21.9 19.8 18.0
High-c county: abbreviation for high-consumption county
1Mean PDD: calculated for all statins from the total volume dispensed in milligrams divided by the total number of dispensed tablets
2The official DDD assigned by the WHO Collaborating Centre for Drug Statistics Methodology, Oslo, Norway [10].Page 4 of 6
(page number not for citation purposes)
BMC Clinical Pharmacology 2007, 7:14 http://www.biomedcentral.com/1472-6904/7/14may most likely be attributed the use of higher dosages,
rather than increased continuity of use.
Overall achievement of TC target among statin users in
our previous study in Hedmark and Oppland were, how-
ever, suboptimal. Only 40–60% of the statin users
achieved the recommended TC target, consistent with
results from other population-based studies in Norway
from the same period [11,12]. Although the presentation
of tablet strength according to the first statin prescription
dispensed do not take into account a future uptitration of
the dose among incident users, it still seems to be a poten-
tial for optimising dosing of statins. For example, in our
study, only 20–30% of all simvastatin users were on doses
corresponding to the dose (40 mg) used in recent pivotal
trials, such as the Heart Protection Study [13].
The observed variations in prevalences of statin use in our
present study, may be explained by previous findings of a
varying threshold for the initiation of statin therapy for
primary prevention between the high- and average-con-
sumption counties Hedmark and Oppland. Interestingly,
this previous study identified a gap between current prac-
tice and guideline recommended level of statin use for pri-
mary prevention in both counties [4]. In this situation, the
variation in prevalence of statin use today may be small
compared with a "scenario" of full implementation of
guidelines in either of the egions.
The prevalence patterns of statin use, however, were simi-
lar in the counties: increasing with age, peaking in the age
group 70–79 years in both sexes. A third of all 70- to 79-
year-old men in the high-consumption county, Hedmark,
had at least one statin prescription dispensed in 2004. As
a comparison, a quarter of all 75-year-old men reported
use of a statin in this county in 2000–1 [4]. The age pat-
tern of current statin use seems to be oriented towards
more extensive use among elderly people, compared with
the situation in the 1990s, where the peak of statin use
was observed in individuals aged ten year younger [14-
16]. This shift could be explained by several factors:
1. First, statin therapy would normally be a lifelong treat-
ment. Naturally, the age of middle-aged patients, in
whom the efficacy was initially documented and therefore
recommended in the 1990s, will increase over time. Most
patients seems adhere to treatment for many years in Nor-
way [17,18] and other populations with comparable
reimbursement systems, such as in Denmark [19,20].
2. Second, recent statin trials have extended our knowl-
edge of the benefit of statin use in elderly people up to
about 80 years of age, in secondary prevention of CVD in
particular [13,21]. Hence, current Norwegian guidelines
now discuss statins for secondary prevention up to this
age [22]. The high prevalence in this age group in our
study may reflect recommendations being adopted in
clinical practice. Corresponding age trends are seen in
Denmark: the 75–84 year olds had the highest relative
increase in statin use in a study of myocardial infarction
(MI) patients in the period 1995–2002 [23].
In our study we found a markedly lower statin use among
those aged 80+ compared with the 70–79 year olds in all
three regions. These figures are parallel to findings from
Norwegian hospitals. The majority of all MI patients aged
up to 80 years were discharged with a statin, compared
with one in ten of those aged 80 and above [17]. Docu-
mentation of beneficial effects of statins in very old peo-
ple is limited, and our observations may reflect the
scepticism among Norwegian doctors to prescribe statins
based on extrapolation from evidence among younger
individuals.
Conclusion
The Norwegian Prescription Database offer new opportu-
nities to study different aspects of statin use in individual
patients, complementary to information attained from
Norwegian health surveys. Differences in age-distribution
cannot fully outweigh the variation in statin consumption
between counties in Norway. Variations in prevalences of
use, and treatment intensity in terms of PDD and choice
of statin also affect the total consumption, which corre-
spond to previous findings of more frequent statin use in
primary prevention, and more statin users achieving lipid
goal in the highest consuming county. The PDDs are
higher than the DDDs, up to twice the DDD for atorvasta-
tin. Interpretation of the published increase in statin
wholesales over the years, with national and international
differences in consumption, should take into account the
age-distribution, the differences in the relationship DDD/
PDD and the choice of statin.
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